Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

2.900 -0.130 (-4.29%)
Streaming Delayed Price Updated: 11:34 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AC Immune SA - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
From AC Immune SA
Via GlobeNewswire
News headline image
Recap: AC Immune Q1 Earnings ↗
AC Immune (NASDAQ:ACIU) reported its Q1 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
AC Immune: Q4 Earnings Insights ↗
AC Immune (NASDAQ:ACIU) reported its Q4 earnings results on Tuesday, March 22, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings AC... 
Via Benzinga
News headline image
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
Via MarketBeat
News headline image
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
News headline image
AC Immune: Q3 Earnings Insights ↗
AC Immune (NASDAQ:ACIU) reported its Q3 earnings results on Friday, October 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings AC Immune beat estimated earnings... 
Via Benzinga
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
News headline image
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win ↗
 
Via Benzinga
News headline image
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Why Zoom Video Is Trading Lower By 11%; Here Are 28 Stocks Moving Premarket ↗
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 58.2% to $0.3070 in pre-market trading. Quotient recently reported a wider Q1 loss. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning! It's time for a breakdown of the biggest pre-market stock movers for Tuesday and the news that has them moving. 
Via InvestorPlace
News headline image
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday ↗
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide ↗
U.S. stocks traded lower toward the end of trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
News headline image
Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher ↗
U.S. stocks traded lower midway through trading, after the Federal Reserve raised fed funds rates by 0.75% to a new target range of between 1.5% and 1.75% on Wednesday. 
Via Benzinga
News headline image
37 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares jumped 153% to $2.94 after the company announced it received notification of euro 782.1 million of funding from the Greek State for the... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; US Jobless Claims Fall To 229,000 ↗
U.S. stocks traded lower this morning, after the Federal Reserve raised interest rates by 0.75% on Wednesday. 
Via Benzinga
News headline image
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. 
Via InvestorPlace
News headline image
27 Stocks Moving in Thursday's Pre-Market Session ↗
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
News headline image
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial ↗
AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction... 
Via Benzinga
News headline image
76 Biggest Movers From Yesterday ↗
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
News headline image
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.